Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Arrests Five SFDA Officials On Bribery Charges

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese authorities earlier this month arrested five officials from the State FDA and the National Institute for the Control of Pharmaceutical and Biological Products for taking bribes, according to reports by the government-run Xinhua News Agency

You may also be interested in...



Former Deputy Director Of China's Drug Regulatory Agency Could Face Trial On Corruption Charges

BEIJING - Eight months after coming under scrutiny of the Chinese Communist Party's top anti-corruption commission, a deputy director of China's State FDA has been expelled from the Party and could face trial, according to central government officials

Former Deputy Director Of China's Drug Regulatory Agency Could Face Trial On Corruption Charges

BEIJING - Eight months after coming under scrutiny of the Chinese Communist Party's top anti-corruption commission, a deputy director of China's State FDA has been expelled from the Party and could face trial, according to central government officials

3SBIO Sees Slowdown In China Regulatory Approvals Following SFDA Restructure; Concerns Linger On Drug Pricing Examination

SHANGHAI - Chinese biotech outfit 3SBio reported strong sales growth of its key products, recombinant human erythropoietin injection EPIAO and recombinant human thrombopoietin injection TPIAO, but like many companies in China, 3SBio's development plans are impacted by a regulatory slowdown caused by restructuring at China's State FDA

Related Content

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel